AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04344418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nurse-performed Focused cardiac ultrasound (FoCUS)
Description: A FoCUS-trained nurse will perform a FoCUS examination within 30 minutes of triage by the triage clinician. The Philips Lumify® handheld ultrasound device (HUD) with a phased array probe will be used and studies limited to a maximum of 10 minutes each. A presumptive diagnosis will then be selected by the nurse from a FoCUS checklist based on pre-defined thresholds for each FoCUS target condition and the time the diagnosis is made recorded. Additional imaging and lab tests may be requested at the discretion of the clinical team but the FoCUS nurses will be blinded to the results of these.
Study NCT04344418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The control arm will consist of usual care ie a combination of physical examination, lab tests and imaging. The need for a formal echocardiographic evaluation by a cardiologist or cardiac sonographer in patients assigned to the control arm will be at the discretion of the clinical teams, as is usual care at KNH and AKUHN
Study NCT04292561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low MAC
Description: To maintain a target of sevoflurane inhalation concentration 0.8 MAC.
Study NCT04292561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High MAC
Description: To maintain a target of sevoflurane inhalation concentration 1.0 MAC.
Study NCT03186911 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: E-liquid sampling and preference assessment
Description: Participants will sample two different e-liquids that vary in nicotine content, complete questionnaires about each one, and then choose between the two e-liquids in a preference assessment task.
Study NCT01137695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide
Description: 120 mcg SQ three times daily for 6 months.
Study NCT01137695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: 360 mcg SQ three times daily for 6 months
Study NCT01137695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide
Description: 120 mcg SQ three times daily for 6 months
Study NCT03818802 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside
Description: It will be administered a total of 1000 mg/day of NR in a regimen of 500mg every 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of 1000mg/day (500mg every 12 hours) for 6 weeks more, completing total of 6 months.
Study NCT03818802 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It will be administered a correspondent placebo with the same shape and color as the active pill 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of correspondent placebo every 12 hours for 6 weeks more, completing total of 6 months.
Study NCT01450709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Kibow Biotics
Description: 6 month, double-blind, cross-over, wash-out, placebo controlled study in an outpatient setting. Each patient takes two capsules, three times a day (180 CFU/day).
Study NCT03510559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forearm Nerve Block
Description: Blockade of the arm below the elbow using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
Study NCT03510559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brachial Plexus Block
Description: Blockade of the entire arm using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
Study NCT02564263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg administered as IV infusion on Day 1 of every 21-day cycle
Study NCT02564263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 80-100 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle
Study NCT02564263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m\^2 administered as IV infusion on Day 1 of every 21-day cycle
Study NCT02564263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: 180 mg/m\^2 administered as IV infusion on Day 1 of every 14-day cycle
Study NCT00442910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% SPL7013 Gel (VivaGel)
Description: 3% vaginal gel
Study NCT00442910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Placebo for SPL7013 gel
Study NCT00442910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC Placebo Gel
Description: HEC Placebo gel intravaginally bd for 14 days
Study NCT02101541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIRM ablation
Description: Radiofrequency catheter ablation of atrial fibrillation driving sources detected by sequential bi-atrial panoramic contact mapping.
Study NCT00784849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene blue
Description: 1 mC1
Study NCT01113268 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cohort
Description: Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
Study NCT01742975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IFABOND (TM)
Description: The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients
Study NCT02844153 — intervention group
Intervention type: OTHER
Intervention: modalities of metformin prescription
Description: Metformin prescription or not, in each CKD stage
Study NCT03532685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric
Description: withdrawing a part of the stomach and may or may not be combined with bowel deviation
Study NCT02445664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Video: Information on osteoporosis and alendronate treatment.
Study NCT03767088 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WB-EMS
Description: whole body electromyostimulation
Study NCT03767088 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: (synchronized) Training program without WB-EMS
Description: 20 min of pronounced eccentric movement patterns
Study NCT01239251 — intervention group
Intervention type: OTHER
Intervention: GlowCap device
Description: Participants will be provided with a device called the GlowCap for a period of 30 days. The device has visual and auditory cues to help patients remember to take their medication at the same time each day. The GlowCap will be programmed to glow when it is time for each patient to take her medication. The GlowCap will initially glow bright orange for the first hour from the time the patient is scheduled to take the medication. During the second hour, the GlowCap system will play music in addition to continuing to glow. If after 2 hours the patient still has not opened the medication bottle, she will receive a phone call reminding her to take her medication.
Study NCT03061409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pharmavite Nature Made Multi for Him 50+
Description: To examine whether one tablet a day of Pharmavite Nature Made Multi for Him 50+ will increase micro-nutrient status in older people taking multiple medications as compared to placebo
Study NCT03061409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: served as placebo
Study NCT02523105 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EEG monitoring
Description: EEG evaluation will be done using two off the shelf EEG devices for research and consumer use. The first one is a device called MindWave by NeuroSky ltd (http://neurosky.com) the second called EPOC by Emotiv ltd (https://emotiv.com/epoc.php).~EEG evaluation will be conducted for a total duration of 20 minutes with and without auditory stimulation. The auditory stimulation will be performed using standard headphone or earphones to reduce external noises.
Study NCT03384719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 35 g protein (30% milk + 70% rapeseed)
Description: The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.
Study NCT03384719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 35 g protein (54% milk + 46% rapeseed)
Description: The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.
Study NCT03384719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 35 g protein (100% milk)
Description: The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.
Study NCT02000856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice
Study NCT02000856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Study NCT03270007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: different from primary chemotherapy(containing anthracycline or paclitaxel)
Study NCT01752257 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: EF5 Hypoxia
Description: EF5 is a dye used to measure hypoxia
Study NCT02636400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: controlled ovarian stimulation with gonadotropins + intrauterine insemination
Study NCT01093209 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Interferential Laser Therapy
Description: PROCEDURE: Interventional group: Two independents and identical probes. Energy dose per point and per probe: 5 J. Continuous emission. Treatment time:8 minutes. Sessions: 10. Frequency of the sessions: daily. Irradiation technique: handily, in contact and at 7 points over distal pathway of median nerve.Control group: Sham laser:650 nm.Scanning mode.Outpout power:1 mW.
Study NCT01093209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Laser Therapy
Description: PROCEDURE: Interventional group: Two independents and identical probes. Energy dose per point and per probe: 5 J. Continuous emission. Treatment time:8 minutes. Sessions: 10. Frequency of the sessions: daily. Irradiation technique: handily, in contact and at 7 points over distal pathway of median nerve.Control group: Sham laser:650 nm.Scanning mode.Outpout power:1 mW.
Study NCT02368405 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in the control group will receive the standard nutrition lecture currently given at Carolinas Rehabilitation to all inpatients with spinal cord injuries. This one lecture is what is required by Commission on Accreditation for Rehabilitation Facilities (CARF)
Study NCT02368405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat Smart, Live Better
Description: Intervention participants will participate in a series of six, 60-minute small group sessions of interactive nutrition education discussions led by a Registered Dietitian delivered over 3 weeks. They will also have one follow-up comprehensive nutrition education session approximately 3 months after receipt of the Eat Smart, Live Better curriculum. In order to help us assess the effectiveness of the nutrition education program, we will assess nutrition behavior and knowledge at this time as well. Community participants in the treatment group will attend the sessions at Carolinas Rehabilitation (CR). The control participants from the community will come to CR for the one standard nutrition lecture. Caregivers and spouses of all of the participants will be encouraged to attend the sessions.
Study NCT03765502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon Device (NG)
Description: NG devices will be provided empty of drug product
Study NCT03765502 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GEK
Description: Used to administer glucagon intramuscularly (IM)
Study NCT03765502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IM Glucagon
Description: Administered IM via GEK
Study NCT01879280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional pterional craniotomy
Description: In the standard pterional craniotomy group, the attachment of the temporalis will be cut and the temporalis will be mobilized prior to exposure of the underlying bony calvarium. This maneuver is currently accepted for use by the majority of neurosurgeons nationwide.
Study NCT01879280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional pterional craniotomy
Description: In the standard pterional craniotomy group, the attachment of the temporalis will be cut and the temporalis will be mobilized prior to exposure of the underlying bony calvarium. This maneuver is currently accepted for use by the majority of neurosurgeons nationwide.
Study NCT01879280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteoplastic craniotomy
Description: In the osteoplastic group, the temporalis will be left attached to the bony calvarium prior to exposure of the tumor. There are ways to turn a bone flap with the temporalis still attached (i.e., an osteoplastic craniotomy). However, this method is thought to be slightly more time-consuming and is used less often in many centers. Aside from the extra time involved, we do not feel that leaving the temporalis attached to the bony calvarium disadvantages the patient in any fashion and may--in fact--result in less post-operative morbidity.
Study NCT01465295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical hemiepiphysiodesis using the HemiBridge System
Description: Surgical application of mechanical hemiepiphysiodesis using the HemiBridge device.
Study NCT04322175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam Eye Drops
Study NCT03919942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OxyFlower gel
Description: the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
Study NCT03919942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel
Description: the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal.
Study NCT03919942 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
Study NCT01245166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose 50 mg, per orem, thrice daily
Study NCT01245166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin/Acarbose
Description: Metformin HCl 500 mg plus Acarbose 50 mg Tablets, per orem, thrice daily
Study NCT03129269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI and PET scan
Description: Neuroimaging with MRI and PET scan Amyloid tracer : For PET-scans, 4 MBq/kg of \[18F\]AV-45 will be injected into each subject in an intravenous bolus.
Study NCT03678636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver antimicrobial dressing
Description: Silver dressing suitable for exudate level
Study NCT03678636 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Usual care for wound type and condition
Study NCT02422823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine
Description: Injection of 1.8mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
Study NCT02422823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine
Description: Injection of 3.6mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
Study NCT02422823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Study NCT03747822 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: fat filler,PEEK,sliding genioplasty
Description: The procedure will be done under general anesthesia; the donor site lower abdomen, flank, lateral thigh, or inner thigh will be infused using a solution that consisted of 100 ml of normal saline with 50 mg (0.05%) of lidocaine and 0.1 ml of epinephrine. Liposuction will be performed using a 2-mm blunt cannula. A 20-cc syringe will be used to collect the fat. The fat will be injected into the chin in a supraperiosteal (subcutaneous) plane with a blunt 2-mm cannula using a fanning technique.
Study NCT03747822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fat filler,PEEK,sliding genioplasty
Description: The procedure will be done under general anesthesia; the donor site lower abdomen, flank, lateral thigh, or inner thigh will be infused using a solution that consisted of 100 ml of normal saline with 50 mg (0.05%) of lidocaine and 0.1 ml of epinephrine. Liposuction will be performed using a 2-mm blunt cannula. A 20-cc syringe will be used to collect the fat. The fat will be injected into the chin in a supraperiosteal (subcutaneous) plane with a blunt 2-mm cannula using a fanning technique.
Study NCT02635100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP machine with MNT algorithm
Description: The multinight (MNT) algorithm will be evaluated on patients with Obstructive Sleep Apnea (OSA) over multiple nights while using CPAP in the home for a total of 45 days. In particular the main goal is to assess the behavior of the two main stages of the algorithm:~1. Fast Track (FT) stage. Assesses if the algorithm reliably and timely reaches approximate therapeutic pressure levels.~2. Slow Titration (ST) stage.Assesses if data samples are appropriately collected in a pressure range so that the therapeutic pressure can be inferred according to the algorithm proposed.~   1. Five days with standard auto titration.~  2. MNT algorithm : 7 days (maximum) with Fast Track mode, 27 days (maximum) in Slow Titration mode. After PMNT is found, the device remains at PMNT for 5 sessions. Total approximately 45 days.
Study NCT01824758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Group L lidocaine (0.5 mg/kg), (rocuronium) (0.05mg/kg).
Study NCT01824758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)
Study NCT01824758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium
Description: 0.05 mg/kg rocuronium
Study NCT01824758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rocuronium
Description: 0.05 mg/kg rocuronium
Study NCT01824758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Description: 0.05 mg/kg rocuronium
Study NCT01824758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)